惠倫晶體(300460.SZ)收到志道投資擬參與公司向特定對象發行股票意向函
格隆匯 3 月 26日丨惠倫晶體(300460.SZ)公佈,安徽志道投資有限公司(“志道投資”)擬參與公司此次向特定對象發行股票事項。截至公吿披露日,公司已收到志道投資擬參與公司向特定對象發行股票的意向函。志道投資與正奇(上海)股權投資管理有限公司(“上海正奇”)合計持有公司的股票佔公司總股本的7.3651%。其中,志道投資持有1400萬股,佔比5.9427%,上海正奇持有335.09萬股,佔比1.4224%。志道投資和上海正奇是正奇金融控股股份有限公司(“正奇金融”)的全資子公司,互為一致行動人,均為公司關聯方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.